MAPT and Alzheimer disease: Administering an OGA inhibitor (an enzyme catalyzing the hydrolytic cleavage of O-GlcNAc) in an AD model of mice points to a reduction in NFTs levels and pathological forms of tau, and slowing disease progression [71].